Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of ibuprofen on bilirubin-albumin binding.

Literature DB >> 15001951

Effect of ibuprofen on bilirubin-albumin binding.

Abstract

Ibuprofen is used for closing the ductus arteriosus in premature newborn infants. Ibuprofen interferes with bilirubin-albumin binding and increases the unbound bilirubin in pooled newborn plasma to levels similar to those produced by sulfisoxazole, a drug that causes kernicterus in premature newborn infants.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15001951 DOI： 10.1016/j.jpeds.2003.11.027

Source DB: PubMed Journal: J Pediatr ISSN： 0022-3476 Impact factor: 4.406

Keyword Cloud
Cited

15 in total

Review 1. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.

Authors: Ronald L Thomas; Graham C Parker; Bart Van Overmeire; Jacob V Aranda
Journal: Eur J Pediatr Date: 2004-12-10 Impact factor: 3.183

2. Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

Authors: Peter Gal
Journal: J Pediatr Pharmacol Ther Date: 2009-01

3. Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.

Authors: Gozde Kanmaz; Omer Erdeve; Fuat Emre Canpolat; Serife Suna Oğuz; Nurdan Uras; Nahide Altug; Ben Greijdanus; Uğur Dilmen
Journal: Eur J Clin Pharmacol Date: 2012-11-06 Impact factor: 2.953

4. Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors: Karen E Corff; Kris C Sekar
Journal: J Pediatr Pharmacol Ther Date: 2007-07

Effect of ibuprofen on bilirubin-albumin binding.

Review 1. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.

2. Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

3. Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.

4. Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

5. Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine.

Review 6. Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Review 7. Bilirubin Binding Capacity in the Preterm Neonate.

Review 8. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus.

Review 9. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

10. Raltegravir in vitro effect on bilirubin binding.